Alexander, Myriam
Loomis, A. Katrina
Fairburn-Beech, Jolyon
van der Lei, Johan
Duarte-Salles, Talita
Prieto-Alhambra, Daniel
Ansell, David
Pasqua, Alessandro
Lapi, Francesco
Rijnbeek, Peter
Mosseveld, Mees
Avillach, Paul
Egger, Peter
Kendrick, Stuart
Waterworth, Dawn M.
Sattar, Naveed
Alazawi, William http://orcid.org/0000-0002-3891-5914
Funding for this research was provided by:
FP7 Ideas: European Research Council (115372)
Article History
Received: 29 March 2018
Accepted: 19 June 2018
First Online: 13 August 2018
Ethics approval and consent to participate
: We followed local data laws in all four territories from which the data were obtained. In all countries, specific ethical approval was not required for this study as it used anonymised data. However, approval was sought and obtained from the scientific research committee for THIN, the IPCI Governing Board (reference 2015/18), the SIDIAP Ethics Committee (reference P15/167) and the scientific committee of the Italian College of General Practitioners and Primary Care.
: Not applicable.
: MA was contracted to work at, and JFB, PE, SK and DW are employees of, GlaxoSmithKline, which has conducted clinical research including trials of therapeutic agents in NAFLD. AKL is an employee of Pfizer, which is conducting clinical research including trials of therapeutic agents in NAFLD. DPA has received unrestricted research grants from UCB, Amgen and Servier, and consultancy fees (paid to his department or research group) from UCB Pharma. DA has provided consultancy and advice to many pharmaceutical companies on undertaking outcome studies using real-world evidence. FL has provided consultancy tor AlfaSigma, Bayer and Abbvie. PE and SK are employees and stockholders of GlaxoSmithKline. NS has consulted for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Janssen, and has received grants from Astrazeneca and BI. WA is a consultant and has delivered sponsored lectures to UCB Pharma, Gilead, Intercept and Medimmune. TDS has no conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.